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Abstract
Behavioral sensitization has been widely studied in animal models and is theorized to reflect
neural modifications associated with human psychostimulant addiction. While the mesolimbic
dopaminergic pathway is known to play a role, the neurochemical mechanisms underlying
behavioral sensitization remain incompletely understood. In the present study, we conducted the
first metabolomics analysis to globally characterize neurochemical differences associated with
behavioral sensitization. Methamphetamine-induced sensitization measures were generated by
statistically modeling longitudinal activity data for eight inbred strains of mice. Subsequent to
behavioral testing, nontargeted liquid and gas chromatography-mass spectrometry profiling was
performed on 48 brain samples, yielding 301 metabolite levels per sample after quality control.
Association testing between metabolite levels and three primary dimensions of behavioral
sensitization (total distance, stereotypy and margin time) showed four robust, significant
associations at a stringent metabolome-wide significance threshold (false discovery rate < 0.05).
Results implicated homocarnosine, a dipeptide of GABA and histidine, in total distance
sensitization, GABA metabolite 4-guanidinobutanoate and pantothenate in stereotypy
sensitization, and myo-inositol in margin time sensitization. Secondary analyses indicated that
these associations were independent of concurrent methamphetamine levels and, with the
exception of the myo-inositol association, suggest a mechanism whereby strain-based genetic
variation produces specific baseline neurochemical differences that substantially influence the
magnitude of MA-induced sensitization. These findings demonstrate the utility of mouse
metabolomics for identifying novel biomarkers, and developing more comprehensive
neurochemical models, of psychostimulant sensitization.
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INTRODUCTION
Repeated administration of psychostimulants, including methamphetamine (MA), results in
a progressive enhancement of the drugs’ behavioral activating effects through a process
known as behavioral sensitization (BSn). Observed in both animal models and humans
(Pierce & Kalivas, 1997, Strakowski & Sax, 1998), BSn is thought to reflect aspects of the
neural adaptations underlying addictive behaviors and motivational states (Robinson &
Berridge, 2008, Steketee & Kalivas, 2011, Wise & Bozarth, 1987). Research into the
neurochemistry of MA-induced BSn has traditionally focused primarily on dopaminergic
neurotransmission. This approach has shown that the psychostimulatory effects of MA are
associated with elevated synaptic dopamine (DA) levels due to increased DA release from
presynaptic terminals and inhibited reuptake, particularly in mesolimbic neurons projecting
from the ventral tegmental area to the nucleus accumbens. Thus, activity-dependent synaptic
plasticity and remodeling of the mesolimbic dopaminergic pathway are known to play an
important role in psychostimulant sensitization and dependence (Nestler, 2001). However,
the neurochemical mechanisms underlying BSn are complex and incompletely understood,
extending beyond mesolimbic DA to include GABAergic and glutamatergic
neurotransmission (Pierce & Kalivas, 1997, Steketee, 2003), as well as recently identified
molecular mediators (e.g., shati and piccolo (Niwa et al., 2008)). While trending toward
broader consideration beyond established pathways, no research to date has applied a
nontargeted metabolomics approach to comprehensively investigate neurochemical variation
associated with BSn.
Metabolomics is an emerging platform that seeks to interrogate the full complement of
endogenous small molecules (typically <1500 Da) within a sample in a nontargeted fashion.
Thus, instead of limiting focus to specific candidate metabolites or metabolic reaction sets,
metabolomics approaches quantitatively assay the entire range of metabolites present in a
sample to characterize its overall biochemical state. Although MA sensitization has not yet
been investigated using metabolomics, the platform has successfully identified biochemical
signatures for other CNS pathologies including schizophrenia, Parkinson’s and motor
neuron disease (Bogdanov et al., 2008, Pears et al., 2005, Prabakaran et al., 2004). Thus,
metabolomics offers the possibility of comprehensively mapping neurochemical profiles
associated with MA-induced BSn, facilitating the identification of novel mechanisms,
biomarkers and therapeutic targets.
To date, metabolomics studies of psychiatric disorders have generally focused on readily
obtained biomaterials in humans (e.g., urine and serum) (Kaddurah-Daouk & Krishnan,
2009). While human metabolomics research has obvious translational clinical potential, it is
also characterized by various limitations including expense, difficulty controlling
confounders and inability to access relevant tissue. Mouse metabolomics circumvent many
of these limitations, cost-effectively providing control of genetic background and
environmental confounders, primary tissues access, and precise behavioral phenotype
measurement (Dunn et al., 2011). These advantages, paired with extensive genomic and
phenotypic database resources, make mouse metabolomics a valuable research strategy for
disorders with robust experimental models (Peters et al., 2007). Following this rationale, we
analyzed the relationship between longitudinal measures of MA-induced BSn and 301
metabolite levels quantified via nontargeted liquid and gas chromatography-mass
spectrometry of 48 murine brain samples.
Adkins et al. Page 2















Male mice aged 7–9 weeks, representing 8 inbred strains chosen to maximize genetic
variability (129S1/SvImJ, A/J, C3H/HeJ, C57BL/6J, CAST/EiJ, DBA/2J, NOD/ShiLtJ,
PWD/PhJ) (Yang et al., 2007), were obtained from Jackson Laboratory (Bar Harbor, ME)
and allowed to acclimate approximately 1week prior to testing. Mice were housed at a
maximum of four per cage in an AAALAC-accredited animal facility with food (7012
Teklad LM-485 Mouse/Rat Sterilizable Diet, Harlan Laboratories, Inc., Indianapolis, IN)
and water available ad libitum under a 12-h/12-h light/dark cycle (lights on at 0700-h to
1900-h). Testing occurred during light phase. All procedures were carried out in accordance
with the “Guide for the Care and Use of Laboratory Animals” (Institute of Laboratory
Animal, 1996) and approved by the Institutional Animal Care and Use Committee of
Virginia Commonwealth University.
Apparatus
Behavioral testing was conducted using 8 commercially obtained, automated activity
monitoring devices, each enclosed in sound- and light-attenuating chambers. Variables
considered potentially relevant BSn indicators included: distance traveled (cm), horizontal
activity (cm), number of movements, resting time (s), stereotypy count, stereotypy number,
stereotypy time (s), margin distance (cm), margin time (s), center time (s) (Supplemental
Methods for variable definitions and selection rationale). Variables were collected in 10-min
bins during 1-h test sessions via computer-controlled circuitry (AccuScan Instruments,
Columbus, OH). Each device’s interior was divided into separate 20×20×30 cm arenas
permitting independent and simultaneous measurement of two mice. Sixteen photobeam
sensors per axis, spaced 2.5 cm apart along the chambers’ walls, were used to detect
movement.
Locomotor Activity Procedure
The behavioral analysis sample included two experimental arms, a 3 mg/kg MA-test group
and a control group receiving vehicle-only injections. MA-test and control groups each
included 64 mice, 8 per strain per arm (128 total). For both arms, Test-day 1 consisted of
two consecutive, 1-h behavioral activity test sessions. A vehicle injection was given
immediately prior to Test-day 1 Session 1 for both groups and vehicle or 3 mg/kg MA
injection, for control and test groups respectively, was given immediately prior to Test-day 1
Session 2. For Test-days 2–4 a single 1-h test session occurred, immediately preceded by
vehicle or 3 mg/kg MA injection, for control and test groups respectively. Test-day 5 exactly
replicated the procedure from Test-day 1. Measurements from the initial, vehicle-only
sessions on Test-days 1 and 5 were excluded from analysis, resulting in 30 repeated
assessments (5 days × 6 bins) per mouse in the behavioral analysis. Boxplots summarizing
all activity data for the MA-test group by day, strain and measure, are presented in
Supplemental Figures 1 and 2.
After the last activity test session, mice were immediately euthanized by microwave fixation
(Muromachi Microwave Fixation System, TMW-4012C, Tokyo). Many neurochemicals
undergo rapid post-mortem alterations due to ongoing metabolism, resulting in a distorted
characterization of in vivo metabolism. These alterations are minimized by microwave
irradiation, which instantaneously denatures all enzymes in the brain, preserving metabolites
in the pre-sacrifice state (De Graaf et al., 2009, Ikarashi et al., 1985, Login & Dvorak,
1994). Brain tissue was then extracted by dissection, placed into 2 ml vials, snap-frozen in
liquid nitrogen and kept frozen at −80°C (Ultima II, ULT2856-9-A40, Thermo Electron
Corporation) prior to shipment to Metabolon. Inc. (Research Triangle Park, NC) for mass
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spectrometry profiling. Forty-eight MA-test mice were selected for whole brain
metabolomics assay (6 randomly selected per strain). Given the study’s aim of
characterizing neurochemicals associated with variation in MA-induced BSn, a phenomenon
only observable with MA administration, vehicle treated controls were not considered in the
metabolomics analysis, but these data have been presented elsewhere (Mcclay et al., 2013).
Drugs
(±)-Methamphetamine (National Institute on Drug Abuse, Rockville, MD) was prepared in
0.9% saline stock solutions sterilized by filtration through 0.2 µm filtration disks. Working
MA solutions were injected intraperitoneally at 10 ml/kg body weight. The 3 mg/kg MA test
dose has been shown to induce sustained behavioral response, persisting longer than test
session duration, in multiple mouse strains (Peachey et al., 1976, Snider et al., 2012, Zhang
et al., 2006).
Metabolomics Sample Preparation
Sample preparation was carried out using the automated MicroLab STAR® system
(Hamilton Robotics, Reno NV) (Evans et al., 2009, Ohta et al., 2009). Recovery standards
were added prior to the first extraction process step for QC purposes. A proprietary
(Metabolon) series of organic and aqueous extractions were used to remove the protein
fraction while maximizing recovery of small molecules. The resulting extract was divided
into liquid chromatography (LC/MS) and gas chromatography (GS/MS) mass spectrometry
fractions. Samples were placed briefly on a TuboVap® (Zymark) to remove the organic
solvent. Each sample was then frozen and dried under vacuum. Samples were then prepared
for either LC/MS or GC/MS. A small aliquot of each experimental sample for a specific
matrix was extracted and pooled together as a “client matrix”. Aliquots of client matrix
samples were injected throughout the platform day run and served as technical replicates. As
such, the variability in the quantitation of all consistently detected biochemicals in the
experimental samples was monitored to provide a process variability metric for run-day
normalization and quality control.
Liquid chromatography/Mass Spectrometry (LC/MS, LC/MS2)
The LC/MS portion of the platform was based on a Waters Acquity UPLC and a Thermo-
Finnigan LTQ mass spectrometer, consisting of an electrospray ionization (ESI) source and
linear ion-trap (LIT) mass analyzer. The sample extract was split into two aliquots, dried,
then reconstituted in acidic or basic LC-compatible solvents, each of which contain ≥11
injection standards at fixed concentrations. One aliquot was analyzed using acidic positive
ion optimized conditions and the other using basic negative ion optimized conditions in two
independent injections using separate dedicated columns. Extracts reconstituted in acidic
conditions were gradient eluted using water and methanol both containing 0.1% formic acid,
while basic extracts, also using water/methanol, contain 6.5mM ammonium bicarbonate.
The MS analysis alternated between MS and data-dependent MS2 scans using dynamic
exclusion.
The LC/MS accurate mass portion of the platform was based on a Surveyor HPLC and a
Thermo-Finnigan LTQ-FT mass spectrometer, which has a linear ion-trap (LIT) frontend
and a Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer backend. For
ions with counts >2 million, an accurate mass measurement can be performed on both parent
ions, as well as fragments. The typical mass error was <5 ppm. Ions with <2 million counts
require greater effort to characterize. Fragmentation spectra (MS/MS) were typically
generated in data dependent manner, but if necessary targeted MS/MS were employed (i.e.,
for lower concentration signals). Further details of LC/MS methods can be found elsewhere
(Evans et al., 2009).
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Gas chromatography /Mass Spectroscopy (GC/MS)
The samples intended for GC/MS analysis were re-dried under vacuum desiccation for a
minimum of 24 hours prior to being derivatized under dried nitrogen using bistrimethyl-
silyl-triflouroacetamide (BSTFA). The GC column is 5% phenyl and the temperature ramp
was from 40° to 300° C in a 16 minute period. Samples were analyzed on a Thermo-
Finnigan Trace DSQ fast-scanning single-quadrupole mass spectrometer using electron
impact ionization. The instrument was tuned and calibrated for mass resolution and mass
accuracy on a daily basis. The information output from the raw data files were automatically
extracted as discussed below. Further details regarding GC/MS methods can be found
elsewhere (Ohta et al., 2009).
Data Extraction and Compound Identification
Raw MS data files were loaded into a relational database and peaks identified using
Metabolon proprietary peak integration software. Biochemicals (and MA) were identified by
comparison to library entries of purified standards or recurrent unknown entities, including
approximately 1500 commercially available purified standard biochemicals for LC and GC
platforms. The combination of chromatographic properties and mass spectra gave an
indication of a match to the specific compound or isobaric entity. As previously described, a
variety of curation and QC procedures were implemented to ensure accurate and consistent
identification of true chemical entities, and to remove those representing system artifacts,
misassignments or background noise, and to confirm the consistency of peak identification
among the various samples (Evans et al., 2009). Biochemicals with <3-fold greater
abundance than background were excluded. A data normalization step was performed to
correct variation resulting from instrument inter-day tuning differences to avoid
confounding experimental variation with instrument sensitivity. Each compound was
corrected in run-day blocks by dividing all samples by that compound’s median (Evans et
al., 2009). Thus, while extraction efficiencies, ionization efficiencies and abundance in
murine brain are variable across metabolites, they are comparable within metabolites,
allowing unbiased comparisons of relative abundance between samples.
Statistical analysis
Linear mixed models were used to model MA-induced BSn effects and generate mouse-
specific sensitization measures for MA-test mice (Willett et al., 1998). It was necessary to
simultaneously model control and MA-test animal data to accurately estimate sensitization
effects by partialling out the effect of protocol habituation (i.e., response to handling and
experimental procedures), which was present in both control and MA-test arms, from BSn,
which was present only in MA arm. For each phenotype, behavioral activity (Y) for each
mouse (i) during each test period (j) was modeled as a function of: (b0) baseline activity
level (i.e., intercept); (b1) habituation, modeled as a linear function of study day; (b2)
baseline effect of MA administration (i.e., dichotomous indicator of experimental arm); (b3)
sensitization to MA exposure, modeled as an interaction between arm and study day; and
mouse-level deviations (random effects) from the mean: (u0i) intercept, (u1i) habituation
effect, and (u3i) sensitization effect; and a residual (eij). This model is formalized as:
Yij = b0 + b1dayij + b2armi + b3armi × dayij + u0i + u1i + u3i + eij
with random effects specified as orthogonal (Willett et al., 1998).
The term of primary interest was the sensitization random effect—u3i. For each of the 10
behavioral phenotypes this term, quantifying the magnitude of each test mouse’s MA-
induced sensitization, was output from the linear mixed model as best linear unbiased
predictors (BLUPs) (Robinson, 1991). Sensitivity analyses modeling the effects of
habituation and sensitization quadratically yielded equivalent (r>0.95) mouse-level
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sensitization estimates. Measures of longitudinal change estimated in this fashion reliably
increase phenotype signal-to-noise ratio, and thus, statistical power, compared to
conventional BSn measurement approaches, such as last minus first MA exposure, or post-
sensitization MA challenge in test and control animals (Willett, 1989, Willett et al., 1998).
Next, to avoid redundant analysis of multiple variables representing the same underlying
sensitization phenomena, we conducted factor analyses to assess dimensionality in the 10
sensitization measure using the standard principle factor method. Several orthogonal
rotations were implemented (e.g., varimax, quartimax) and yielded comparable three factor
solutions. Additionally, one way ANOVA were used to calculate the proportion of variance
explained by strain (i.e., heritability) for all sensitization and metabolite measures.
Primary metabolomics analyses were conducted as a series of bivariate linear regressions,
with a separate model estimated for each metabolite-sensitization combination, resulting in
903 total associations (301 metabolites × 3 outcomes). As mice are nested within strains,
they are nonindependent, which violates regression assumptions and generally downwardly
biases standard errors, increasing Type I errors (Williams, 2000). To account for
nonindependence of mice within strains, the Huber/White/Sandwich clustered variance
estimator was used to calculate standard errors (Rogers, 1994, Williams, 2000). This method
explicitly adjusts for within-cluster (i.e., strain) correlation, allowing unbiased significance
testing of clustered data and efficient use of all available information. For each sensitization
outcome, false discovery rate (FDR) methods used to adjust significance criterion for
multiple testing. As argued previously (Van Den Oord & Sullivan, 2003), we prefer an
FDR-based approach to declaring significance because it: (a) balances competing goals of
finding true effects versus avoiding false discoveries, (b) provides comparable standards
across studies, as it is less affected by number of tests and importantly, (c) is relatively
robust to correlated tests (Fernando et al., 2004, Storey, 2003), as were present here. We
used an FDR<0.05 threshold for declaring metabolome-wide significance, specifying that,
on average, 5% of associations declared significant are expected to be false discoveries.
Operationally, FDR levels were controlled using q-values (Storey, 2003).
Additionally, we conducted several sensitivity analyses to test the robustness of the
metabolome-wide significant associations. First, to eliminate the possibility that the
observed metabolite differences reflect acute MA response, we adjust for levels of
locomotor activity observed in the first test session again using cluster-robust standard
errors. Second, to eliminate the possibility that metabolome-wide significant associations are
driven by outlying mice, we calculate Spearman rank correlations with cluster-robust
standard errors. Third, analyses were repeated systematically excluding one strain at a time,
to ensure that statistical significance was not driven by a single outlying strain. Only
associations satisfying these three sensitivity criteria (p<0.05) were considered robust and
included in the final sets of analyses.
Next, multiple regression was used to consider whether the robustly significant metabolite-
outcome associations were mediated by concurrent MA level in brain and/or genetic
differences between strains. To this end, we compared sensitization variance explained by
metabolite level in a bivariate regression model (R2) to marginal sensitization variances
explained by metabolite level controlling for MA level (R2M) and strain (R2S), respectively.
R2M and R2S were calculated as a partial R2 (Cohen et al., 2003). Substantively, a partial R2
may be interpreted as the additional variance explained by the metabolite, over and above
that explained by the putative mediator. Heritability (H2) was calculated and is defined as
the proportion of the sensitization-metabolite covariance explained by strain. Lastly, we
collapsed metabolite levels into strain means and examined the correlations of these
metabolite strain means between the MA-test mice analyzed here and mice sacrificed at
baseline (i.e., no MA exposure). This was done to investigate the degree to which associated
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metabolites reflected baseline strain differences. All formulae are detailed in Supplemental
Methods.
RESULTS
As expected, results indicated that for all 10 phenotypes the mean behavioral activating
effects of MA significantly sensitized with repeated administration (p<0.05; Supplemental
Figure 3). The degree of sensitization significantly varied across individual mice (p<.05;
Supplemental Table 1). For each phenotype, measures quantifying mouse-specific MA-
induced BSn were extracted from linear mixed models as BLUPs (Robinson, 1991). All BSn
measures were approximately normally distributed with no significant outliers/skewness
(Supplemental Figure 4). Factor analysis of sensitization measures indicated three
substantial factors underlying the measures (explaining 91% cumulative variance). Factor 1
(65% variance) was well-represented by sensitization in total distance (TD) (λ=0.97), Factor
2 (15% variance) by stereotypy number (SN) (λ=0.78), and Factor 3 (11% variance) by
margin time (MT) (λ=0.74) (Supplemental Table 2; Supplemental Figure 5). These three
BSn measures were used as metabolomics outcomes and raw data used to generate them is
presented, by strain, in longitudinal scatterplots with superimposed strain mean trajectories
in Figure 1. ANOVA results indicated that these three sensitization measures varied in
heritability, with approximately half of sensitization variance due to strain differences for
TD (p=6.60E-06, R2=0.46) and SN (p=9.63E-06, R2=0.45), while a nonsignificant
proportion of sensitization variance was attributable to strain for MT (p=0.19, R2=0.15). See
Supplemental Table 3 for ANOVA results for strain effects on all 10 behavioral indicators.
Metabolomics association analyses were conducted as a series of 903 bivariate linear
regressions using cluster-robust standard errors, one for each metabolite-outcome
combination. Q-Q plots show that associations were generally stronger than expected by
chance, with nine associations achieving metabolome-wide significance (q<0.05), 2 for TD,
5 for SN and 2 for MT (Figure 2). Specifically, TD was significantly associated with
ribulose and homocarnosine. SN was significantly associated with isovalerylcarnitine,
pantothenate, glutarylcarnitine, N-acetylglutamate and 4-guanidinobutanoate. MT was
significantly associated with betaine and myo-inositol (Table 1). All results were robust to
adjusting for the acute locomotor effects of MA. However, Spearman rank sensitivity
analyses indicated that the ribulose-TD, glutarylcarnitine-SN, N-acetylglutamate-SN and
betaine-MT associations were driven by outlying mice. Similarly, sensitivity analyses
examining the influence of individual strains indicated outlying metabolite levels among
129S1/SvImJ drove the isovalerylcarnitine-SN association. Consequently, these five non-
robust associations are excluded from further analysis (Supplemental Figure 6). The four
robust associations are visualized in Figure 3. As shown by standardized regression
coefficients (β column, Table 1), for each of the robust associations a 1 SD change in
metabolite level was associated with 0.35–0.5 SD change in the corresponding BSn
measure. Thus, metabolite levels explained 12–25% of sensitization outcome variance in
bivariate models (R2 column, Table 1). Among the robustly significant metabolites,
ANOVA results indicated high heritability for homocarnosine (p=5.12E-17, R2=0.89),
pantothenate (p=1.40E-07, R2=0.66) and 4-guanidinobutanoate (p=1.62E-13, R2=0.83), and
nonsignficant heritability for myo-inositol (p=0.17, R2=0.21). Strain ANOVA results for all
301 assayed metabolites, summarized in Supplemental Figure 7, demonstrate significant
heritability (p<0.05) for a majority (68.8%) of metabolites, and high heritability (h2>0.70)
for substantial minority (13.0%) of metabolites.
Next, to determine whether the observed robustly significant associations were a direct
result of concurrent MA level, we adjusted the sensitization-metabolite associations for MA
level in brain homogenate at sacrifice. Results indicated that MA level did not significantly
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mediate associations, with marginal metabolite-sensitization associations remaining highly
significant (p<.001) (Figure 4; Supplemental Table 4). Next, we adjusted the metabolite-
sensitization associations for strain differences to determine to what extent significant
associations were due to genetic differences. Results indicated that associations were
generally largely determined by genetic variation between strains, with marginal metabolite
effects attenuated to nonsignificant levels when adjusting for strain for homocarnosine-TD,
pantothenate-SN and 4-guanidinobutanoate-SN (p>.05; Figure 4). The myo-inositol-MT
association was an exception—it was not substantially influenced by strain differences, with
its marginal metabolite-sensitization association remaining large and significant (p<.001;
Figure 4). These results were consistent with one way ANOVA results showing significant
heritability for all implicated metabolites and sensitization outcomes, with the exceptions of
myo-inositol and MT.
Finally, we collapsed metabolite levels into strain means and examined the correlations of
the metabolite strain means between the MA-test mice analyzed here and mice sacrificed at
baseline (i.e., no MA exposure). The rationale for this analysis is that if, (a) the strain
differences explain a large majority of metabolite-sensitization associations, and (b) the
correlations of strain metabolite means pre- and post- MA sensitization are high, it can be
transitively inferred that, (c) significant results reflect associations between baseline strain
neurochemical differences and sensitization. This proved to be the case for metabolites in
associations substantially accounted for by strains differences, with homocarnosine
(p=0.0001, R2=0.94), pantothenate (p=0.0001, R2=0.94) and 4-guanidinobutanoate
(p=0.0003, R2=0.90) all showing a very high degree of correspondence between strain
means pre- and post- MA sensitization. A lower, though still substantial, correlation was
observed for myo-inositol (p=0.013, R2=0.67), further suggesting a unique mechanism for
the myo-inositol-MT association relative to the other robust associations. The full results of
pre- and post-sensitization strain mean correlations for all 301 assayed metabolites are
summarized in Supplemental Figure 8 and indicate variable correlation strength, but with far
more significant associations than expected by chance (61.8% at p<0.05).
DISCUSSION
Here we report the first nontargeted metabolomics analysis to globally characterize
neurochemical differences associated with MA-induced BSn. Association testing between
sensitization measures and 301 mass spectrometry-derived metabolite levels, measured
across eight inbred mouse strains, identified four novel, robust BSn-metabolite associations.
Previous research indicates plausible biological mechanisms for several of these
associations.
In addition to the primary sensitization metabolomics association analysis, we also analyzed
the longitudinal activity data and metabolite battery separately. Results from our activity
phenotype modeling yielded several notable findings. First, mean MA-induced BSn was
significant across all activity measures and the magnitude of sensitization varied markedly
across strains (Supplemental Figure 3; Figure 1). While previous research on strain
differences in psychostimulant BSn has yielded mixed findings due to modest statistical
power, the strain differences observed here were consistent with the most commonly
reported patterns, showing increased BSn in DBA/2J and C57BL/6J, particularly relative to
A/J and 129/J strains (Chen et al., 2007, Eisener-Dorman et al., 2011, Mead et al., 2002,
Thomsen & Caine, 2011). Next, consistent with findings from BXD recombinant inbred
strains (Philip et al., 2010), we found that strain accounted for a significant proportion of
sensitization variance (h2=33–50%, p<0.001) for all sensitization phenotypes except margin
time (h2=15%, p=0.19) (Supplemental Table 3). Independent analyses of the metabolite
battery indicated that heritability ranged widely for the 301 metabolites considered, with
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most metabolites significantly heritable, many metabolites, including homocarnosine
(h2=89%), highly heritable, but 31.2% of metabolites, including myo-inositol, showing
nonsignificant heritability (p<0.05) (Supplementary Figure 7).
Results from the primary association analyses of MA-induced activity sensitization (TD, SN
and MT) and the 301 brain metabolites indicated four metabolite-sensitization associations
were metabolome-wide significant (q<0.05) and satisfied all sensitivity criteria:
homocarnosine-TD (β=−0.50, p=2.25E-05), pantothenate-SN (β=0.47, p=1.29E-04), 4-
guanidinobutanoate-SN (β=−0.35, p=4.59E-04) and myo-inositol-MT (β=−0.47,
p=4.86E-04) (Figure 3). Among these implicated metabolites, the association of
homocarnosine to TD provides clear biological rationale, suggesting that strain-based
differences in homocarnosine-mediated cortical excitability moderate the magnitude of MA-
induced psychomotor sensitization. This interpretation is supported by research showing that
homocarnosine, a CNS dipeptide of GABA and histidine, is intimately related to
GABAergic function and serves as a potent inhibitory neuromodulator (Petroff et al.,
1998b). Brain homocarnosine levels dose-dependently increase in response to antiepileptic
drugs including vigabatrin and topiramate, with the degree of homocarnosine increase
strongly correlating with seizure control (Petroff et al., 1998a, Petroff et al., 1999).
Moreover, homocarnosine has been indirectly implicated in MA-induced sensitization by
studies showing that vigabatrin is effective in treating psychostimulant dependence (Brodie
et al., 2005, Gerasimov et al., 1999). Vigabatrin is thought to influence psychostimulant
addiction through tonically inhibiting both endogenous and psychostimulant-induced
extracellular striatal DA release (Dewey et al., 1992, Gerasimov et al., 1999). Additional
clinical research has shown that homocarnosine’s cortical inhibitory effects are relevant to
several related outcomes, including alcohol dependence and panic disorder (Behar et al.,
1999, Goddard et al., 2001).
Homocarnosine’s neural function remains incompletely understood. Although it has been
established that hydrolysis of homocarnosine can rapidly liberate GABA in brain, the
balance of evidence suggests that homocarnosine most likely exerts inhibitory effects in of
itself, without conversion to GABA (Jackson et al., 1994, Petroff, 2002). This is supported
by recent studies of homocarnosine function in rat hippocampus indicating that while both
homocarnosine and GABA exerted inhibitory effects, homocarnosine showed no effect on
membrane potential; its effects were blocked by pretreatment with GABAA inhibitors; and
its presence reduced the frequency but not the burst characteristics of induced seizure-like
activity (Petroff & Williamson, 2009). Thus, consistent with our findings, it appears that
homocarnosine’s inhibitory action does not function through increasing GABA levels, but
rather through shifting the balance from intracellular to synaptic locations of
neurotransmitter.
The 4-guanidinobutanoate-SN association suggests a related GABAergic mechanism. 4-
guanidinobutanoate is a relatively poorly studied metabolite formed by the transfer of the
guanidino group from arginine to GABA via transamination (Jansen et al., 2006, Schulze et
al., 1998). While research on the neural function of this metabolite is sparse, there is some
indication that it exerts GABAergic effects in rodent CNS (Bowery & Brown, 1974).
Intriguingly, as with homocarnosine, 4-guanidinobutanoate levels are elevated by vigabtrin
treatment (Schulze et al., 1998). These facts, combined with the substantial correlation
observed with homocarnosine in the current data (r=0.58; p<0.001), suggest that 4-
guanidinobutanoate is plausible biomarker of GABAergic inhibition and perhaps a causal
factor in attenuating MA-induced BSn.
The myo-inositol-MT association is also consistent with previous research. Margin time, or
thigmotaxis, is a well-established index of anxiety in mice, which has been validated using
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several anxiogenic and anxiolytic drugs (Simon et al., 1994). Consistent with our results,
there is a large body of research in both rodents and humans indicating a negative
correlation between CNS myo-inositol levels and anxiety disorders /behaviors (Benjamin et
al., 1995, Einat & Belmaker, 2001). This research has demonstrated that chronic myo-
inositol administration, but not acute, increases open field activity in rodents and that
chronic exposure increases rodent myo-inositol levels in various brain regions, including
cortex and hippocampus (Cohen et al., 1997, Einat & Belmaker, 2001). Human postmortem
research has shown that reduced myo-inositol levels in frontal cortex are associated with
bipolar disorder and suicide, suggesting that endogenous levels are relevant to anxiety-
related phenotypes (Shimon et al., 1997). While the precise mechanism by which myo-
inositol exerts its anxiolytic effects remains obscure, the metabolite is a key precursor of the
phosphoinositide secondary messenger cycle, which is activated following ligand binding
with G-protein coupled receptors across several neurotransmitter systems including
serotonergic (5-HT1C and 5-HT2) and dopaminergic (D1) receptor types (Kim et al., 2005).
Finally, the pantothenate-SN finding is entirely novel, with no notable support from
previous research.
Synthesizing all results yields a consistent causal interpretation, with the notable exception
of the myo-inositol-MT finding. Thus, the homocarnosine-TD, 4-guanidinobutanoate-SN
and pantothenate-SN associations all share several notable features—all of these metabolites
and sensitization dimensions are highly heritable in this mouse panel; strain means of the
metabolites are virtually perfectly correlated between untreated and MA sensitized mice;
and the covariances of metabolites and sensitization measures are highly heritable.
Furthermore, analyses controlling for acute MA activity effects and MA brain levels at
sacrifice rule out the possibilities that these findings reflect differences in MA metabolism
rates or the acute activity-inducing effects of MA. Additionally, none of the significant
associations identified here overlap findings from our previous metabolomics analysis of the
direct neurochemical effects of MA exposure (Mcclay et al., 2013). Cumulatively, these
findings strongly suggest that baseline strain differences in the implicated neurochemicals
substantially influence the magnitude MA-induced TD and SN sensitization.
The myo-inositol-MT finding suggests a different, and less certain, causal interpretation.
Unlike the other significant associations, myo-inositol and MT were not significantly
heritable in this sample, nor was their covariance. Furthermore, the correlation of strain
means in untreated and MA sensitized mice indicated substantially less stability than was
observed for the other significant metabolites. Thus, this finding is not attributable to strain
differences and it is possible that the association may be due to myo-inositol levels
differentially shifting as a consequence of repeated MA exposure, rather than baseline
neurochemical differences. Given the causal ambiguity of this finding, it may be reasonable
to regard it with a heightened degree of skepticism. However, the result is entirely consistent
with a large body of previous research showing negative correlations between CNS myo-
inositol levels and anxiety traits, including open field measures similar to MT (Einat &
Belmaker, 2001, Shimon et al., 1997), supporting its validity as a true discovery.
These results suggest promising directions for future research. Given that the predominant
pattern in the significant findings suggests common genetic variation producing baseline
neurochemical differences that then substantially predict the magnitude of MA-induced
sensitization, future research using a heterogeneous, genetically diverse sample of mice,
such as latter generations of the Collaborative Cross (Iraqi et al., 2012), would be
advantageous for several reasons. First, the increased genetic diversity would offer greater
statistical power and reduce the risk of spurious association (Flint & Eskin, 2012). Second,
genomewide genotypes are freely available for the founder strains and hundreds of crosses
of the Collaborative Cross panel (Iraqi et al., 2012), enabling inexpensive genetic mapping
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of both metabolite levels and sensitization variables. Notwithstanding these merits, an
awareness of the limits of generalizability between mouse models and humans is warranted
given known species differences in potentially relevant neurochemical pathways, such as
neuroactive steroid modulation of GABAergic signaling (Nguyen et al., 1995).
Another topic relevant to future research is the use of whole brain homogenate in the current
study, the selection of which was influenced by volume requirements for the nontargeted
metabolomic assay (Evans et al., 2009, Ohta et al., 2009). While, in principle, volume
requirements could have been met through pooling specific regions across mice within
strains, implicit in such pooling is the strong assumption of no within-strain variance, which
would have precluded investigating heritability and missed the myo-inositol-MT finding,
which was driven by within-strain variance. Another, more general limitation of the
metabolomics platform is its exclusive focus on changes to the overall metabolite pool.
Thus, highly localized effects, such as synaptic release of neurotransmitters, will not be
detectable in the tissue homogenate because it is impossible to distinguish between, for
example, vesicular and synaptic neurotransmitter molecules. Despite these limitations, the
multiple robust signals detected here demonstrate the method’s value as a screening tool.
Clearly, this is only the first stage in understanding the role of these metabolites in
psychostimulant abuse. Accordingly, we encourage future research into the roles of the
implicated metabolites in targeted assays of candidate brain regions.
In conclusion, using nontargeted metabolomic profiling, we identified multiple
neurochemical signatures in MA-induced sensitization. Specific results include the finding
that relative abundance of two specific GABAergic metabolites, homocarnosine and 4-
guanidinobutanoate, attenuate the magnitude of MA psychomotor sensitization. Further,
consistent with previous research, we found myo-inositol negatively associated with
sensitization of MA’s anxiogenic effects. While the estimated risk of false discoveries was
quite low, independent replication and targeted follow-up will be necessary to confirm and
elaborate these findings. To facilitate this, we have made p-values from the primary analysis
available for download (http://www.people.vcu.edu/~ejvandenoord/) as a resource
supporting future replication, follow-up or data integration efforts. It is hoped that this
research will encourage further metabolomics applications to identify novel neurochemical
mechanisms and potential therapeutic targets in neuropsychiatric disorders.
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Figure 1. Longitudinal scatterplots, by strain, of all MA-test mice repeated assessments for
behavioral outcomes used in metabolomics analyses
Mean strain sensitization trajectories are superimposed over scatterplots. A stochastic jitter
was used to prevent overlay of points occurring on the same day.
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Figure 2. Nine neurochemical levels were significantly associated with MA-induced BSn (q<0.05)
Q-Q plots compare observed −log(10) p-values to expected –log(10) p-values under the null
distribution for bivariate associations of BSn measures (a Total distance, b Stereotypy
number, c Margin time) to 301 neurochemical levels. Each point represents a
neurochemical-BSn association p-value and points falling above the null expectation,
represented by the dark gray line, are higher than expected by chance. Light gray lines
indicate 95% confidence intervals for each p-value rank. All metabolome-wide significant p-
values are labeled.
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Figure 3. Associations of homocarnosine to TD, pantothenate and 4-guanidinobutanoate to SN,
and myo-inositol to MT were robust across the examined inbred strain panel
Sensitivity analyses indicated that the statistical significance of these associations was robust
to outlying mice and the exclusion of any single strain.
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Figure 4. Among robust associations, neurochemical concentrations explained 12–25% of BSn
variance and, with the exception of myo-inositol, were largely mediated by genetic differences
The first columns (light gray) describe unconditional BSn variance explained by the
metabolite, with R2 ranging from 0.251 (homocarnosine) to 0.121 (4-guanidinobutanoate)
(p<.001; bars represent s.e.m.). The second columns (dark gray) describe marginal BSn
variance explained by metabolite adjusting for concurrent MA brain levels (partial R2), with
R2m remaining highly significant (p<.001). The third columns (medium gray) represents the
metabolite partial R2 adjusting for strain, which was nonsignificant for homocarnosine,
pantothenate and 4-guanidinobutanoate (p>.05), but significant for myo-inositol (p<.001).
Thus, estimates of the proportion of metabolite-BSn associations explained by strain were
high (H2=0.70–0.99) for all associations except myo-inositol (H2=0.06), as shown in the
final column (black) of each panel.
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